J. Smolen, R. Landewé, F. Breedveld, M. Buch, G. Burmester et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, vol.69, issue.(Suppl), pp.492-509, 2014.
DOI : 10.1136/annrheumdis-2013-204573

O. Meyer, C. Labarre, M. Dougados, P. Goupille, A. Cantagrel et al., Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage, Annals of the Rheumatic Diseases, vol.62, issue.2, pp.120-126, 2003.
DOI : 10.1136/ard.62.2.120

R. Audo, B. Combe, M. Hahne, and J. Morel, The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis, Cytokine, vol.63, issue.2, pp.81-90, 2013.
DOI : 10.1016/j.cyto.2013.04.011

S. Lamhamedi-cherradi, S. Zheng, K. Maguschak, J. Peschon, and Y. Chen, Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL???/??? mice, Nature Immunology, vol.4, issue.3, pp.255-60, 2003.
DOI : 10.1038/ni894

K. Song, Y. Chen, R. Göke, A. Wilmen, C. Seidel et al., Tumor Necrosis Factor???Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression, The Journal of Experimental Medicine, vol.155, issue.7, pp.1095-104, 2000.
DOI : 10.1016/S1074-7613(00)80400-8

A. Anel, A. Bosque, J. Naval, A. Pineiro, L. Larrad et al., Apo2L/TRAIL and immune regulation, Frontiers in Bioscience, vol.12, issue.1, pp.2074-84, 2007.
DOI : 10.2741/2212

J. Morel, R. Audo, M. Hahne, and B. Combe, Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Induces Rheumatoid Arthritis Synovial Fibroblast Proliferation through Mitogen-activated Protein Kinases and Phosphatidylinositol 3-Kinase/Akt, Journal of Biological Chemistry, vol.280, issue.16, pp.15709-15727, 2005.
DOI : 10.1074/jbc.M414469200

N. Takahashi, N. Udagawa, and T. Suda, A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function, Biochemical and Biophysical Research Communications, vol.256, issue.3, pp.449-55, 1999.
DOI : 10.1006/bbrc.1999.0252

G. Schett, K. Redlich, S. Hayer, J. Zwerina, B. Bolon et al., Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice, Arthritis & Rheumatism, vol.20, issue.Suppl 1, pp.2042-51, 2003.
DOI : 10.1002/art.11150

R. Knevel, D. De-rooy, T. Saxne, E. Lindqvist, M. Leijsma et al., A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis, Arthritis Research & Therapy, vol.16, issue.3, p.108, 2014.
DOI : 10.1038/ng.479

S. Vitovski, J. Phillips, J. Sayers, and P. Croucher, Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-??B or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS, Journal of Biological Chemistry, vol.282, issue.43, pp.31601-31610, 2007.
DOI : 10.1074/jbc.M706078200

R. Audo, F. Calmon-hamaty, D. Baeten, A. Bruyer, B. Combe et al., Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.11, issue.4, pp.904-917, 2011.
DOI : 10.1002/art.30181

B. Combe, J. Benessiano, F. Berenbaum, A. Cantagrel, J. Daurès et al., The ESPOIR cohort: A ten-year follow-up of early arthritis in France, Joint Bone Spine, vol.74, issue.5, pp.440-445, 2007.
DOI : 10.1016/j.jbspin.2007.06.001

D. Van-der-heijde, M. Van-leeuwen, P. Van-riel, and L. Van-de-putte, Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification), J Rheumatol, vol.22, pp.1792-1798, 1995.

K. Visser, Y. Goekoop-ruiterman, J. De-vries-bouwstra, H. Ronday, P. Seys et al., A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study, Annals of the Rheumatic Diseases, vol.69, issue.7, pp.1333-1340, 2010.
DOI : 10.1136/ard.2009.121160

M. Meyer, J. Sellam, S. Fellahi, S. Kotti, J. Bastard et al., Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort, Arthritis Research & Therapy, vol.15, issue.6, p.210, 2013.
DOI : 10.1111/j.1365-2265.2012.04348.x

URL : https://hal.archives-ouvertes.fr/inserm-00926603

G. Tobón, A. Saraux, C. Lukas, F. Gandjbakhch, J. Gottenberg et al., First-Year Radiographic Progression as a Predictor of Further Progression in Early Arthritis: Results of a Large National French Cohort, Arthritis Care & Research, vol.6, issue.Suppl 1, pp.1907-1922, 2013.
DOI : 10.1002/acr.22078

E. Halpern, M. Albert, A. Krieger, C. Metz, and A. Maidment, Comparison of receiver operating characteristic curves on the basis of optimal operating points, Academic Radiology, vol.3, issue.3, pp.245-53, 1996.
DOI : 10.1016/S1076-6332(96)80451-X

S. Greenhouse, J. Cornfield, and F. Homburger, The Youden index: Letters to the editor, Cancer, vol.3, issue.6, pp.1097-101, 1950.
DOI : 10.1002/1097-0142(1950)3:6<1097::AID-CNCR2820030620>3.0.CO;2-E

L. Nahidi, S. Leach, D. Lemberg, and A. Day, Osteoprotegerin Exerts Its Pro-inflammatory Effects Through Nuclear Factor-??B Activation, Digestive Diseases and Sciences, vol.40, issue.11, pp.3144-55, 2013.
DOI : 10.1007/s10620-013-2851-2

S. Bernardi, B. Fabris, M. Thomas, B. Toffoli, C. Tikellis et al., Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes, Molecular and Cellular Endocrinology, vol.394, issue.1-2, pp.13-20, 2014.
DOI : 10.1016/j.mce.2014.06.004

S. Colucci, G. Brunetti, F. Cantatore, A. Oranger, G. Mori et al., The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis, Apoptosis, vol.278, issue.6, pp.1623-1655, 2007.
DOI : 10.1007/s10495-007-0095-3

E. Chamoux, N. Houde, L. Eriger, K. Roux, and S. , Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway, Journal of Cellular Physiology, vol.214, issue.2, pp.536-578, 2008.
DOI : 10.1002/jcp.21430

G. Brunetti, A. Oranger, G. Mori, R. Tamma, D. Benedetto et al., TRAIL Is Involved in Human Osteoclast Apoptosis, Annals of the New York Academy of Sciences, vol.1116, issue.1, pp.316-338, 2007.
DOI : 10.1196/annals.1402.011

I. Pettersen, Y. Figenschau, E. Olsen, W. Bakkelund, B. Smedsröd et al., Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human articular chondrocytes in vitro, Biochemical and Biophysical Research Communications, vol.296, issue.3, pp.671-677, 2002.
DOI : 10.1016/S0006-291X(02)00916-6

N. Courvoisier, M. Dougados, A. Cantagrel, P. Goupille, O. Meyer et al., Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study, Arthritis Research & Therapy, vol.10, issue.5, p.106, 2008.
DOI : 10.1186/ar2498

URL : https://hal.archives-ouvertes.fr/hal-00375615

N. Vastesaeger, S. Xu, D. Aletaha, S. Clair, E. Smolen et al., A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis, Rheumatology, vol.48, issue.9, pp.1114-1135, 2009.
DOI : 10.1093/rheumatology/kep155